{"id":410248,"date":"2021-01-07T08:03:13","date_gmt":"2021-01-07T13:03:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410248"},"modified":"2021-01-07T08:03:13","modified_gmt":"2021-01-07T13:03:13","slug":"aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Jan.  07, 2021  (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, Ph.D., MBA, will present at the 39<sup>th<\/sup>\u00a0Annual J.P. Morgan Healthcare Conference\u00a0on\u00a0Monday, January 11, 2021 at 3:40 p.m. ET\/12:40pm PT. The presentation will be followed by a virtual Q&amp;A session.<\/p>\n<p align=\"left\">A recording of the webcast presentation will be available within 24 hours of the presentation and will be available for 30 days through the Investors section of the Aligos website. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HAgBcewqpTexxOzAuoTxKua9oYclyQoPden5siKJDrPohMyjO_DFMiPz1-u8CL-VhWJNz84PqtHmNpeGDcmBoXK0EqL4OfNle3Z6KSpTSbE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/investor.aligos.com<\/a><\/p>\n<p align=\"left\">\n        <strong>About Aligos<\/strong>\n      <\/p>\n<p align=\"left\">Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos\u2019 strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statement<\/strong>\n      <\/p>\n<p align=\"left\">This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered \u201cforward-looking statements\u201d. Forward-looking statements are typically, but not always, identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos\u2019s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos\u2019s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos\u2019s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos\u2019s prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.<\/p>\n<p align=\"left\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Amy Jobe, Ph.D.<br \/>LifeSci Communications<br \/>+1 315 879 8192<br \/>ajobe@lifescicomms.com<\/p>\n<p align=\"left\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>+1 212 915 2577<br \/>cdavis@lifesciadvisors.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/72c79631-2b0e-466d-9302-f32f6accb539\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, Ph.D., MBA, will present at the 39th\u00a0Annual J.P. Morgan Healthcare Conference\u00a0on\u00a0Monday, January 11, 2021 at 3:40 p.m. ET\/12:40pm PT. The presentation will be followed by a virtual Q&amp;A session. A recording of the webcast presentation will be available within 24 hours of the presentation and will be available for 30 days through the Investors section of the Aligos website. https:\/\/investor.aligos.com About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410248","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, Ph.D., MBA, will present at the 39th\u00a0Annual J.P. Morgan Healthcare Conference\u00a0on\u00a0Monday, January 11, 2021 at 3:40 p.m. ET\/12:40pm PT. The presentation will be followed by a virtual Q&amp;A session. A recording of the webcast presentation will be available within 24 hours of the presentation and will be available for 30 days through the Investors section of the Aligos website. https:\/\/investor.aligos.com About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission &hellip; Continue reading &quot;Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T13:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-07T13:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":529,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=\",\"datePublished\":\"2021-01-07T13:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, Ph.D., MBA, will present at the 39th\u00a0Annual J.P. Morgan Healthcare Conference\u00a0on\u00a0Monday, January 11, 2021 at 3:40 p.m. ET\/12:40pm PT. The presentation will be followed by a virtual Q&amp;A session. A recording of the webcast presentation will be available within 24 hours of the presentation and will be available for 30 days through the Investors section of the Aligos website. https:\/\/investor.aligos.com About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission &hellip; Continue reading \"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T13:03:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-07T13:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":529,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=","datePublished":"2021-01-07T13:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjAwMCMzOTA4NDMyIzIyMDM5MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410248"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410248\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}